ClinicalTrials.gg
Not yet recruitingNCT07251062Updated Nov 26, 2025

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

A Phase 2/3 interventional study of SYS6010+SG001+ physician's choice (Capecitabine or 5-FU) and Investigator's choice of SOC in Esophageal Squamous Cell Carcinoma, sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd.. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by CSPC Megalith Biopharmaceutical Co.,Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
737
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter phase 2/3 clinical study to evaluate the efficacy and safety of SYS6010 plus SG001±5-FU/Capecitabine as first-line treatment, in patients with advanced/metastatic esophageal squamous cell carcinoma.

Read the detailed description

Phase II study comprises a safety lead-in stage, a dose expansion stage, and a randomized treatment stage. The Phsae III study is randomized controlled trial.

Phase II (safety lead-in stage): the safety lead-in stage employs a 3+3 design. It aims to evaluate the safety and tolerability of combination therapy-comprising capecitabine/5-FU administered at a descending dose level starting from DL0 alongside fixed doses of SYS6010 and SG001-in previously untreated patients with unresectable locally advanced or metastatic ESCC. The primary objectives are to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D).

Phase II (dose expansion stage): Upon completion of the safety evaluation and confirmation of tolerability for a dose cohort in the safety lead-in phase, expansion of that cohort may be initiated, with plans to expand 1-2 dose cohorts.

Phase II (randomized treatment stage): Upon determination of the RP2D based on prior data, a randomized controlled study will be conducted in a first-line advanced/metastatic esophageal squamous cell carcinoma (ESCC) patient population. Patients will be randomly assigned to three arms: Arm 1: SYS6010+SG001+ capecitabine/5-FU; arm2: investigator's choice of SOC; arm3: SYS6010+SG001.

Phase III is a randomized, controlled, open-label, multicenter study designed to evaluate the efficacy of SYS6010+SG001+capecitabine/5-FU versus investigator's choice of treatment as first-line therapy for advanced/metastatic esophageal squamous cell carcinoma. The Phase III trial design will be finalized based on Phase II results. The preliminary plan is to randomized patients in a 1:1 ratio to either the investigational arm or the control arm. Investigational arm: SYS6010+SG001+capecitabine/5-FU; control arm: investigator's choice of SOC.

02

Conditions studied

  • Esophageal Squamous Cell Carcinoma
03

In context

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

This study's planned enrollment of 737 is above the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.

Browse Esophageal Squamous Cell Carcinoma studies →

Lead sponsor

CSPC Megalith Biopharmaceutical Co.,Ltd. is the lead sponsor of 42 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be able to understand and voluntarily sign the written ICF;
  2. Age 18-75 (inclusive) years, male or female;
  3. With histologically/ confirmed esophageal squamous cell carcinoma that is either locally advanced unresectable or , with no prior systemic antitumor therapy administered for the recurrent/metastatic disease setting. Have at least one that meets the v 1.1 criteria at baseline;
  4. (ECOG) performance status score: 0-1;
  5. ≥ 3 months;

Exclusion criteria

Exclusion Criteria:

  1. Prior treatment involving topoisomerase I inhibitors (including ADC drugs that contain topoisomerase I inhibitors as toxins);
  2. Prior treatment with or other agents targeting T-cell co-stimulatory/co-inhibitory pathways (e.g., anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-CD137 antibodies)
  3. With a history of ≥Grade 3 allergic reactions to monoclonal antibodies, or with known or intolerance to SYS6010, SG001, paclitaxel, carboplatin, cisplatin, fluorouracil, or any of their ;
  4. With dihydropyrimidine dehydrogenase (DPD) deficiency.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
737 participants (estimated)

Study arms

  • Experimental
    Phase II (Safety lead-in stage) : SYS6010+SG001+physician's choice(Capecitabine or 5-FU )

    Drug: SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)

  • Experimental
    Phase II (dose expansion stage): SYS6010+SG001+physician's choice (Capecitabine or 5-FU)

    Upon completion of the safety evaluation and confirmation of tolerability for a dose cohort in the safety run-in phase, expansion of that cohort may be initiated, with plans to expand 1-2 dose cohorts.

    Drug: SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)

  • Experimental
    Phase II(randomized Controlled stage): SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)

    Drug: SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)

  • Active comparator
    PhaseII(randomized treatment stage): physician's choice of SOC

    Drug: Investigator's choice of SOC

  • Experimental
    Phase II(randomized controlled stage): SYS6010+SG001

    Drug: SYS6010+SG001

  • Active comparator
    Phase III: SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)

    Drug: SYS6010+SG001+ physician's choice (Capecitabine or 5-FU)

  • Active comparator
    Phase III: physician's choice of SOC

    Drug: Investigator's choice of SOC

Interventions

  • DrugSYS6010+SG001+ physician's choice (Capecitabine or 5-FU)

    SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker. SG001 is a recombinant, fully human, anti-PD-1 monoclonal antibody. Capecitabine: Capecitabine is for oral administration. 5-FU: Administration at the conventional dosage.

    Also known as: SG001: Enlonstobart

  • DrugInvestigator's choice of SOC

    1. Camrelizumab + Cisplatin + Paclitaxel 2. Tislelizumab + Cisplatin + Paclitaxel 3. Tislelizumab + Cisplatin + 5-FU/Capecitabine

  • DrugSYS6010+SG001

    Drug pages: Anti-EGFR Antibody-drug Conjugate CPO301 · Enlonstobart

    SYS6010 is an antibody conjugate drug (ADC), composed of one anti-EGFR monoclonal antibody coupled to one JS1 via an enzyme specific linker. SG001 is a recombinant, fully human, anti-PD-1 monoclonal antibody.

06

What researchers measure

Primary outcomes

  1. PhaseII(safety leadrun-in stage): DLT; Description: Dose-limiting toxicity

    Dose-limiting toxicity

    Time frame: 28 days

  2. PhaseII(safety run-inlead-in stage): AE

    The incidence and severity of Adverse events

    Time frame: From the signing of the informed consent form until 90 days after the last dose.

  3. PhaseII(safety leadrun-in stage): MTD;

    Maximum tolerated dose

    Time frame: After phase II saftysafety run-inlead-in stage and dose expansion stage. Approximately 4 months.

  4. PhaseII(safety run-inlead-in stage): RP2D

    Recommended Phase II dose

    Time frame: After phase II saftysafety run-inlead-in stage and dose expansion stage. Approximately 4 months.

  5. PhaseII(Randomized treatment stage): ORR per RECIST v1.1

    Objective response rate

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.

  6. PhaseIII: PFS-ICR

    PFS assessed by independent review committee

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  7. PhaseIII: OS;

    Overall survival

    Time frame: Through study completion, up to approximately 5 year.

Secondary outcomes

  1. Phase II: DOR per RECIST 1.1;

    Duration of response.

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  2. Phase II: DCR per RECIST 1.1;

    Disease of controll

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  3. Phase II:PFS per RECIST 1.1

    Progression free survival

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years

  4. Phase II:OS

    Overall survival

    Time frame: Through study completion, up to approximately 5 year

  5. Phase II: Serum concentrations of toxin-bound antibodies, total antibodies, and JS-1 following single and multiple doses of SYS6010

    Serum concentrations of toxin-bound antibodies, total antibodies, and JS-1 following single and multiple doses of SYS6010

    Time frame: From first dose of treatment to 30 days after the last dose of treatment.

  6. Phase II: plasma concentration of SG001 following single and multiple doses of SG001;

    Plasma concentration of SG001 following single and multiple doses of SG001

    Time frame: From first dose of treatment to 30 days after the last dose of treatment.

  7. Phase II: EGFR protein expression and PD-L1 protein expression;

    EGFR protein expression and PD-L1 protein expression;

    Time frame: From first dose of treatment to 30 days after the last dose of treatment.

  8. Phase II: The incidence and titer of anti-drug antibodies (ADA), as well as the incidence of neutralizing antibodies (NAb) (if applicable), for SYS6010.

    The incidence and titer of anti-drug antibodies (ADA), as well as the incidence of neutralizing antibodies (NAb) (if applicable), for SYS6010.

    Time frame: From first dose of treatment to 30 days after the last dose of treatment.

  9. Phase II: The incidence and titer of anti-drug antibodies (ADA), as well as the incidence of neutralizing antibodies (NAb) (if applicable), for SG001;

    The incidence and titer of anti-drug antibodies (ADA), as well as the incidence of neutralizing antibodies (NAb) (if applicable), for SG001.

    Time frame: From first dose of treatment to 30 days after the last dose of treatment.

  10. Phase III: DOR-IRC per RECIST 1.1

    Duration of response assessed by independent review committee

    Time frame: Weeks 8, 12, 18, every 6 weeks within 48 weeks, and every 12 weeks thereafter, until the end of the study

  11. Phase III: DCR-IRC per RECIST 1.1;

    Disease of controll assessed by independent review committee.

    Time frame: Weeks 8, 12, 18, every 6 weeks within 48 weeks, and every 12

  12. Phase III:PFS per RECIST 1.1;

    Progression free survival

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.

  13. Phase III:ORR-IRC;

    Objective response rate assessed by independent review committee

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years.

  14. Phase III: AE;

    Incidence and severity of adverse events

    Time frame: From first dose of treatment to 90 days after the last dose of treatment.

  15. Phase III: Serum concentrations of toxin-bound antibodies, total antibodies, and JS-1 following single and multiple doses of SYS6010;

    Serum concentrations of toxin-bound antibodies, total antibodies, and JS-1 following single and multiple doses of SYS6010

    Time frame: From first dose of treatment to 30 days after the last dose of treatment.

  16. Phase III: plasma concentration of SG001 following single and multiple doses of SG001

    Plasma concentration of SG001 following single and multiple doses of SG001

    Time frame: From first dose of treatment to 30 days after the last dose of treatment.From first dose of treatment to 30 days after the last dose of treatment.

  17. Phase III: EGFR protein expression and PD-L1 protein expression

    EGFR protein expression and PD-L1 protein expression

    Time frame: From first dose of treatment to 30 days after the last dose of treatment.

  18. Phase III: The incidence and titer of anti-drug antibodies (ADA), as well as the incidence of neutralizing antibodies (NAb) (if applicable), for SYS6010 .

    The incidence and titer of anti-drug antibodies (ADA), as well as the incidence of neutralizing antibodies (NAb) (if applicable), for SYS6010.

    Time frame: From first dose of treatment to 30 days after the last dose of treatment.

  19. The incidence and titer of anti-drug antibodies (ADA), as well as the incidence of neutralizing antibodies (NAb) (if applicable), for SG001

    The incidence and titer of anti-drug antibodies (ADA), as well as the incidence of neutralizing antibodies (NAb) (if applicable), for SG001

    Time frame: From first dose of treatment to 30 days after the last dose of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2025; primary completion for Dec 2029, 48 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 26, 2025
StartEst.
Dec 30, 2025
Primary completionEst.
Dec 30, 2029
CompletionEst.
Dec 30, 2030
Last update
Nov 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07251062
Responsible party
Sponsor
First posted
Nov 26, 2025
Start date
Dec 30, 2025 (estimated)
Primary completion
Dec 30, 2029 (estimated)
Completion
Dec 30, 2030 (estimated)
Last update
Nov 26, 2025

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
0311-69085587

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-EGFR Antibody-drug Conjugate CPO301 · Enlonstobart

Start the discussion